

STATEMENT OF APPROVED BUDGET, UTILIZATION, DISBURSEMENTS AND BALANCES FOR TRUST RECEIPTS
(for Implementing Agency use only)
As of the Quarter Ending March 31, 2021

Department : State Universities and Colleges (SUCs)
Agency : University of the Philippine System
Operating Unit : University of the Philippines, Manila
Organization Code(UACS) :
Fund Cluster : 07 - Trust Receipts
Date Exported : April 10, 2021, 06:10:05 PM

Inter Agency Fund Transfer

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budget Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
		3	4	5=(3+(-4))	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
Dangeroous Drugs Board	2020105000	4,000,000.00		4,000,000.00											4,000,000.00		
	2020105000	4,000,000.00		4,000,000.00											4,000,000.00		
UPM Development and Validation of a Plastic-Based Microfluidic POCT-Device (E-as) Used to Detect Intoxication With Selected New Psychoactive Substances and Pharmaceuticals (104)	2020105000	4,000,000.00		4,000,000.00											4,000,000.00		
PS	2020105000	2,052,979.20		2,052,979.20											2,052,979.20		
MOOE	2020105000	1,787,020.80		1,787,020.80											1,787,020.80		
CO	2020105000	160,000.00		160,000.00											160,000.00		
UPM Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), A RANDOMIZED TRIAL (107-142)	2020105000	2,979,324.23		2,979,324.23											2,979,324.23		
PS	2020105000	2,209,964.60		2,209,964.60											2,209,964.60		
MOOE	2020105000	769,359.63		769,359.63											769,359.63		
UPM Digital Histologic Image Analysis Software for Hirschsprung's Disease (107-95)	2020105000	644,966.80		644,966.80											644,966.80		
MOOE	2020105000	644,966.80		644,966.80											644,966.80		
UPM Intra-lesional Zoonotic Transmission of Schistosomiasis in Leyte, the Philippines (107-137)	2020105000	1,852,122.02		1,852,122.02	150.00				150.00	150.00				150.00	1,851,972.02		
PS	2020105000	577,387.20		577,387.20											577,387.20		
MOOE		1,274,734.82		1,274,734.82	150.00				150.00	150.00				150.00	1,274,584.82		
DOST		570,886,868.36		570,886,868.36	314,173.48				314,173.48	314,173.48				314,173.48	569,772,694.88		
		570,886,868.36		570,886,868.36	314,173.48				314,173.48	314,173.48				314,173.48	569,772,694.88		
UPM Operations Research on the Implementation of the Single Joint Ethics Review Process (107-87)		428,387.65		428,387.65											428,387.65		
MOOE		428,387.65		428,387.65											428,387.65		
UPM Performance of a Dengue Anti-NS1 Assay for the Determination of Dengue Serostatus Among Children in the Philippines (107-107)	2020105000	5,000,000.00		5,000,000.00											5,000,000.00		
CO	2020105000	5,000,000.00		5,000,000.00											5,000,000.00		
UPM Project 1. Biomarkers of Immune Dysfunction in HIV-Associated Metabolic and Neurocognitive Complications (107-138)	2020105000	52,404,574.00		52,404,574.00	150.00				150.00	150.00				150.00	52,404,424.00		
PS	2020105000	3,157,320.00		3,157,320.00											3,157,320.00		
MOOE		1,552,254.00		1,552,254.00	150.00				150.00	150.00				150.00	1,552,104.00		
CO	2020105000	47,695,000.00		47,695,000.00											47,695,000.00		
UPM Project 1.4-FIX: Design and Fabrication of External Fixator (107-132)	2020105000	10,242,440.48		10,242,440.48	150.00				150.00	150.00				150.00	10,242,290.48		
PS	2020105000	2,257,513.60		2,257,513.60											2,257,513.60		
MOOE		3,494,926.88		3,494,926.88	150.00				150.00	150.00				150.00	3,494,776.88		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=3+(-4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12 +13+14)	16=(5-16)	17	18
CO	2020105000	4,490,000.00		4,490,000.00											4,490,000.00		
UPM Project 1: Cessation of Tobacco (Rugby) Addiction in Adolescents: Using a Rodent Model to Test Novel Pharmacological and Behavioral Treatments for Overcoming Withdrawal and Craving (107-130)	2020105000	16,780,143.49		16,780,143.49											16,780,143.49		
PS	2020105000	2,603,486.40		2,603,486.40											2,603,486.40		
MOOE	2020105000	4,176,657.09		4,176,657.09											4,176,657.09		
CO	2020105000	10,000,000.00		10,000,000.00											10,000,000.00		
UPM Project 1: Next Generation Sequencing-based ex vivo profiling of Breast Cancer among Filipinos and Prediction of Response to Neoadjuvant Therapy for Locoregionally-advanced Breast Cancer in Filipinos (107-139)	2020105000	14,852,066.40		14,852,066.40											14,852,066.40		
PS	2020105000	3,701,692.80		3,701,692.80											3,701,692.80		
MOOE	2020105000	6,850,393.60		6,850,393.60											6,850,393.60		
CO	2020105000	4,300,000.00		4,300,000.00											4,300,000.00		
UPM Project 2 OR PETALS: Operating Room Programmable Electronically Targeted Active Lighting System (107-133)	2020105000	10,968,664.32		10,968,664.32	150.00				150.00	150.00				150.00	10,968,664.32		
PS	2020105000	2,549,438.40		2,549,438.40											2,549,438.40		
MOOE		3,247,875.92		3,247,875.92	150.00				150.00	150.00				150.00	3,247,875.92		
CO	2020105000	5,171,300.00		5,171,300.00											5,171,300.00		
UPM Project 3: Development of a Safe Lactic Acid Bacteria (Lab)-Based Biofunctional Health-Promoting Food as an Adjunct Intervention for the Management of HIV-Associated Metabolic Complications (107-136)	2020105000	13,237,226.68		13,237,226.68	150.00				150.00	150.00				150.00	13,237,226.68		
PS	2020105000	2,358,350.40		2,358,350.40											2,358,350.40		
MOOE		1,423,876.28		1,423,876.28	150.00				150.00	150.00				150.00	1,423,876.28		
CO	2020105000	9,455,000.00		9,455,000.00											9,455,000.00		
UPM Project 3, I-Blood: A Compact Device for Measuring Intraoperative Blood Loss in Used Surgical Gauze and Laparotomy packs (107-134)	2020105000	5,317,768.78		5,317,768.78	150.00				150.00	150.00				150.00	5,317,768.78		
PS	2020105000	1,971,955.20		1,971,955.20											1,971,955.20		
MOOE		1,697,813.58		1,697,813.58	150.00				150.00	150.00				150.00	1,697,813.58		
CO	2020105000	1,648,000.00		1,648,000.00											1,648,000.00		
UPM Project 4: Surgical Innovation and Biotechnology Laboratory (SIBOL): Establishment of the University of the Philippines College of Medicine (UPCM) - PGH SIBOL (107-135)	2020105000	6,056,723.51		6,056,723.51	150.00				150.00	150.00				150.00	6,056,723.51		
PS	2020105000	2,581,281.60		2,581,281.60											2,581,281.60		
MOOE		3,475,441.91		3,475,441.91	150.00				150.00	150.00				150.00	3,475,441.91		
UPM Solidarity Vaccine Trial in the Philippines: Randomized Trial of Candidate Vaccines of COVID-19 (107-118)		429,322,490.00		429,322,490.00	313,123.48				313,123.48	313,123.48				313,123.48	429,009,366.52		
PS		196,316,358.00		196,316,358.00	313,123.48				313,123.48	313,123.48				313,123.48	196,003,234.52		
MOOE	2020105000	216,214,787.00		216,214,787.00											216,214,787.00		
CO	2020105000	16,791,345.00		16,791,345.00											16,791,345.00		
PhilHealth	2020105000	203,551.56		203,551.56											203,551.56		
	2020105000	203,551.56		203,551.56											203,551.56		
Validating the Performance of the National Health Insurance Program	2020105000	203,551.56		203,551.56											203,551.56		
MOOE	2020105000	203,551.56		203,551.56											203,551.56		
PITARC	2020105000	399,823.98		399,823.98											399,823.98		
	2020105000	399,823.98		399,823.98											399,823.98		
Formulation and in vivo Evaluation Studies of Syrup and Tablet Containing Alternanthera sessilis and Phyllanthus niruri aqueous Crude Extracts for Anemia and Thrombocytopenia (Phase 1) 165-16	2020105000	399,823.98		399,823.98											399,823.98		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
PS	2020195000	267,004.00		267,004.00											267,004.00		
MOOE		132,819.98		132,819.98											132,819.98		
GRAND TOTAL		574,699,243.90		574,699,243.90	314,173.48				314,173.48	314,173.48				314,173.48	574,376,070.42		
PS		223,604,731.30		223,604,731.30	313,123.48				313,123.48	313,123.48				313,123.48	222,291,607.72		
MOOE		247,374,867.70		247,374,867.70	1,050.00				1,050.00	1,050.00				1,050.00	247,373,817.70		
CO		104,719,645.00		104,719,645.00											104,719,645.00		

Certified Correct:


 LOVELLE C. SAGUID
 Chief Budget Officer
 Date: 4/12/21

Certified Correct:


 ERWIN A. DANDO, CPA
 Chief Accountant
 Date: 04.12.2021

Recommended By:


 MICHAEL L. TEE, MD, MHPED
 Vice Chancellor for Planning and Development
 Date:

Approved By:


 CARMENCITA D. PADILLA, MD, MAHPS
 Chancellor
 Date: 20 APR 2021